Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Baili Tianheng: BL-ARC002 for Advanced Solid Tumor Treatment Receives Clinical Trial Approval Notice
People’s Financial News, March 22 — Baili Tianheng (688506) announced on March 22 that the company recently received an official approval notice from the National Medical Products Administration (NMPA) for clinical trials of a drug. The company’s self-developed innovative drug, BL-ARC002 injection (referred to as “BL-ARC002”), has been approved for clinical trials. According to the Drug Administration Law of the People’s Republic of China and relevant regulations, after review, the clinical trial of BL-ARC002 meets the requirements for drug registration, and approval has been granted to conduct clinical trials for advanced solid tumors.